Reaction

Middle Ear Effusion reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,169 reports · 58 co-occurring drugs

As of the last recalculation, Middle Ear Effusion appears in 2,169 FAERS reports alongside 58 co-occurring drug terms. The strongest observed disproportionality signal is DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED (PRR 14.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Diphenhydramine Hydrochloride Capsule, Liquid Filled	31	14.1	14.1
Epoprostenol	17	12.6	12.6
Dimenhydrinate	13	11.8	11.8
Azelastine	19	10.2	10.2
Meclizine	16	9.5	9.5
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	20	9.4	9.4
Naproxen Sodium, Pseudoephedrine Hydrochloride	20	9.4	9.4
Ciclesonide	13	9.2	9.2
Adrenalinum	39	9.2	9.2
0Xygen	46	9.1	9.1
Oxygen	46	9.1	9.1
Thyroid, Porcine	10	9.0	9.1
Meclizine Hydrochloride	18	8.9	8.9
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hcl	45	8.8	8.8
Cephalexin	19	8.5	8.5
Cetirizine Hcl	8	8.4	8.4
Fluticasone Propionate Nasal	26	8.3	8.3
Fluticasone Propionate	104	8.0	8.0
Meclizine Hcl 12.5Mg	11	7.8	7.8
Meclizine Hcl 25Mg	11	7.8	7.8
Meclizine Hcl 12.5 Mg	11	7.8	7.8
Meclizine Hcl 25 Mg	11	7.8	7.8
Tiotropium Bromide Inhalation Spray	9	7.7	7.7
Riociguat	25	7.4	7.4
Tadalafil	74	7.3	7.3
Selexipag	19	7.1	7.1
Epinephrine	47	7.0	7.0
Ambrisentan	88	7.0	7.0
Guaifenesin	22	7.0	7.0
Macitentan	48	6.8	6.8
Treprostinil	78	6.1	6.2
Buspirone Hydrochloride	7	6.1	6.1
Calcium, Magnesium, Potassium, And Sodium Oxybates	5	5.6	5.6
Fexofenadine Hydrochloride	12	5.3	5.3
Lanreotide Acetate	4	4.9	4.9
Ibrutinib	40	4.8	4.8
Asfotase Alfa	5	4.8	4.8
Acalabrutinib	6	4.8	4.8
Bimekizumab	10	4.5	4.5
Omalizumab	39	4.5	4.5
Sodium Oxybate	30	4.4	4.4
Loratadine And Pseudoephedrine Sulfate	3	3.6	3.6
Pegvaliase-Pqpz	3	3.5	3.5
Voclosporin	3	3.3	3.3
Diroximel Fumarate	4	3.2	3.2
Avapritinib	4	3.2	3.2
Alirocumab	8	3.1	3.1
Ixazomib	8	2.7	2.7
Pseudoephedrine Hcl	3	2.6	2.6
Lifitegrast	4	2.4	2.4
Abaloparatide	7	2.3	2.3
Nemolizumab-Ilto	3	2.3	2.3
Ixekizumab	8	2.1	2.1
Dupilumab	83	1.7	1.7
Evolocumab	28	1.7	1.7
Pirfenidone	7	1.7	1.7
Pomalidomide	17	1.6	1.6
Apremilast	19	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.